FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Leukemia topics
Myelogenous
Myelogenous Leukemia
Proliferative
Autoimmune
Stem Cells
Breast Cancer
Rheumatoid Arthritis
Myeloid Leukemia
Acute Myelogenous Leukemia
Lymphocytic
Chronic Lymphocytic Leukemia
Lymphocytic Leukemia
Epigenetic
Multiple Myeloma
Polyphenol

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Leukemia patents



      
           
This page is updated frequently with new Leukemia-related patent applications. Subscribe to the Leukemia RSS feed to automatically get the update: related Leukemia RSS feeds. RSS updates for this page: Leukemia RSS RSS


Cardiac glycoside analogs in combination with emodin for cancer therapy

Date/App# patent app List of recent Leukemia-related patents
07/24/14
20140206694
 Heterocyclic compounds and their uses patent thumbnailnew patent Heterocyclic compounds and their uses
Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (sle), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, the present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as acute myeloid leukaemia (aml) myelo-dysplastic syndrome (mds) myelo-proliferative diseases (mpd) chronic myeloid leukemia (cml) t-cell acute lymphoblastic leukaemia (t-all) b-cell acute lymphoblastic leukaemia (b-all) non hodgkins lymphoma (nhl) b-cell lymphoma and solid tumors, such as breast cancer.. .
07/24/14
20140206631
 Cardiac glycoside analogs in combination with emodin for cancer therapy patent thumbnailnew patent Cardiac glycoside analogs in combination with emodin for cancer therapy
A method and medicine for treating leukemia or other cancer includes administering to a patient diagnosed with leukemia or other cancer a treatment regimen that includes periodic doses of a combination of emodin and digoxin.. .
07/24/14
20140206624
 Treatment of leukemia patent thumbnailnew patent Treatment of leukemia
Compositions and methods for the treatment of leukemia by inhibiting foxo signaling are described.. .
07/24/14
20140205680
 Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer patent thumbnailnew patent Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
Methods of treating, preventing or managing cancer, including certain leukemias are disclosed. The methods encompass the administration of enantiomerically pure (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid.
07/24/14
20140205568
 Promyelocytic leukemia protein as a redox sensor patent thumbnailnew patent Promyelocytic leukemia protein as a redox sensor
The present invention relates to a method for determining the redox status of a cell or tissue comprising a step consisting of determining the level of pml nuclear bodies in said cell or tissue.. .
07/17/14
20140200247
 Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazoles orotate formulations patent thumbnailNovel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazoles orotate formulations
New polymorphs of 5-amino or substituted amino 1,2,3-triazole and substituted derivatives thereof, of orotates of the carboxyamidotriazoles, of formulations of the triazoles and orotic acid in the ratio of 1:1 to 1:4 (base:acid) and of safer processes of the preparation of the same are disclosed. The compounds are useful in the control and treatment of diseases including, but not limited to solid cancers, macular degeneration, retinopathy, chronic myeloid leukemia, aids and diseases which rely on aberrant signal transduction.
07/17/14
20140200245
 Inhibitors of c-fms kinase patent thumbnailInhibitors of c-fms kinase
Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..
07/17/14
20140199378
 New natural and synthetic compounds for treating cancer and other diseases patent thumbnailNew natural and synthetic compounds for treating cancer and other diseases
This invention provides a method of synthesizing new active compounds for pharmaceutical uses including cancer treatment, wherein the cancers comprise breast, leukocytic, liver, ovarian, bladder, prostatic, skin, bone, brain, leukemia, lung, colon, cns, melanoma, renal, cervical, esophageal, testicular, spleenic, kidney, lymphatic, pancreatic, stomach and thyroid cancers. This invention is an anti-adhesion therapy which uses the compound as a mediator or inhibitor of adhesion proteins and angiopoietins.
07/10/14
20140194632
 Method for screening for compounds selectively interacting with rad9 patent thumbnailMethod for screening for compounds selectively interacting with rad9
Natural and synthetic compounds of formulae ia-ie having a lactone structure, in particular securolide, have been determined to be effective anti-tumor compounds which target the hrad9 gene and/or protein encoded thereby or complex containing the protein and/or the p53 gene and/or protein. Securolide is cytoselective for mutants of hrad9 based on studies conducted in rad9 mutant yeast strains.
07/10/14
20140193420
 Diagnosis and treatment of cancer using anti-itm2a antibody patent thumbnailDiagnosis and treatment of cancer using anti-itm2a antibody
Disclosed is a monoclonal antibody binding to an itm2a protein. This antibody is useful in the diagnosis, prevention, and treatment of cancer such as ewing's sarcoma, t cell leukemia, t cell lymphoma, acute myeloid leukemia, b cell tumor, and multiple myeloma.
07/10/14
20140193333
Therapeutic and diagnostic target
The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of acute myeloid leukemia (aml), b-cell chronic lymphocytic leukemia, breast cancer, colorectal cancer, kidney cancer, head and neck cancer, lung cancer, ovarian cancer or pancreatic cancer, for monitoring the effectiveness of acute myeloid leukemia (aml), b-cell chronic lymphocytic leukemia, breast cancer, colorectal cancer, kidney cancer, head and neck cancer, lung cancer, ovarian cancer or pancreatic cancer treatment, and for drug development. The present invention also provides methods and compositions for depletion of immune cells to treat inflammatory diseases..
07/03/14
20140187604
Therapeutic and diagnostic target gene in acute myeloid leukemia
Methods are provided for treating a cancer in a subject comprising administering to the subject an agent which inhibits expression of an hlx gene in the subject, or an agent which inhibits activity of an expression product of the hlx gene, and also for diagnosing a subject as likely to develop a cancer comprising determining whether a stem cell obtained from the subject expresses a hlx gene at a level in excess of predetermined control level. Kits therefor are also provided..
07/03/14
20140186376
Compositions and methods for inhibiting ccl3
The present invention relates to the discovery that ccl3, through at least one of its receptors ccr1 and ccr5, plays a role in the pathologies associated with myeloid neoplasms. In various embodiments, the pathologies associated with myeloid neoplasms treatable by the compositions and methods of the invention described herein include, but are not limited to, at least one of osteoclast/osteoblast imbalance, inhibition of osteoblast function, bone loss, disregulation of the hematopoietic stem cell microenvironment, abnormal hematopoietic recovery, pancytopenia, anemia, thrombocytopenia, neutropenia, bicytopenia, and erythrocytopenia.
06/26/14
20140179626
Acadesine derivatives, products and compositions including same, therapuetic uses thereof, and methods for synthesizing same
Acadesine derivatives as a drug, as well as the derivatives for the treatment of cancer and in particular for the treatment of chronic myeloid leukemia are described. Also, product containing the derivatives and at least one second active ingredient as a combination product for simultaneous, separate or sequential administration, in the treatment of cancer, as well as a pharmaceutical composition containing the derivatives and a pharmaceutically acceptable carrier are described.
06/19/14
20140172321
Leukemia classification using cpd data
Embodiments of the present invention encompass automated systems and methods for predicting an acute leukemia sub-type of an individual diagnosed with acute leukemia based on a biological sample obtained from blood of the individual. Exemplary techniques involve correlating aspects of direct current (dc) impedance, radiofrequency (rf) conductivity, and/or light measurement data obtained from the biological sample with an acute leukemic sub-type of the individual..
06/12/14
20140161825
Methods of treating acute myeloid leukemia by blocking cd47
Methods are provided to manipulate phagocytosis of cancer cells, including e.g. Leukemias, solid tumors including carcinomas, etc..
06/12/14
20140161805
Methods for manipulating phagocytosis mediated by cd47
Methods are provided to manipulate phagocytosis of cells, including hematopoietic cells, e.g. Circulating hematopoietic cells, bone marrow cells, etc.; and solid tumor cells.
06/05/14
20140155635
Resorcylic acid lactone compounds
Disclosed are a novel resorcyclic acid lactone compound with inhibitory activity against protein kinases, a pharmaceutically acceptable salt thereof, a method for the synthesis thereof, and a pharmaceutical composition for the treatment and prevention of various cancer diseases comprising the same as an active ingredient. The novel resorcyclic acid lactone compound is useful as a therapeutic for cancer diseases, especially blood cancer, inter alia, acute myeloid leukemia (aml)..
06/05/14
20140154304
Combination therapy with volasertib
Disclosed is the use of volasertib or a salt or a hydrate thereof for treating patients suffering from acute myeloid leukemia (aml) comprising administering a high dose of volasertib in combination with fludarabine, cytarabine and granulocyte colony-stimulating factor (gcsf) or in combination with fludarabine, cytarabine, gcsf and a daunorubicin citrate liposome injection.. .
05/29/14
20140148448
Inhibitors of c-fms kinase
Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..
05/29/14
20140148394
Compositions and methods for modulating gamma-c-cytokine activity
The various embodiments relate to peptide antagonists of γc-family cytokines, interleukin-2 (il-2), interleukin-4 (il-4), interleukin-7 (il-7), interleukin-9 (il-9), interleukin-15 (il-15), and interleukin-21 (il-21). The γc-cytokines are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (gvhd).
05/29/14
20140148377
Emetine derivatives, prodrugs containing same, and methods of treating conditions using same
Compounds are provided herein which are emetine derivatives that can be used as prodrugs which selectively undergo activation to release emetine in specific cellular conditions. In one aspect, a blocking group is incorporated onto the emetine molecule by the derivization of the n2′-position with moieties that can be selectively removed by hydrolysis in the cancer/tumor microenvironment.
05/29/14
20140148354
Methods and compositions for identifying minimal residual disease in acute lymphoblastic leukemia
This invention provides methods and kits for diagnosing, ascertaining the clinical course of minimal residual disease associated with acute lymphoblastic leukemia (all). Specifically the invention provides methods and kits useful in the diagnosis and determination of clinical parameters associated with diseases associated with all based on patterns of surface marker expression unique to all..
05/29/14
20140148351
Prediction of clinical outcome in hematological malignancies using a self-renewal expression signature
Methods, compositions, and kits are provided for providing a diagnosis, a prognosis, or a prediction of responsiveness to a therapy for a patient with a hematological malignancy. In practicing the subject methods, the expression level of at least one leukemia stem cell (lsc) genes in a tissue sample is assayed to obtain an lsc expression representation.
05/29/14
20140147834
Kit for detecting bovine leukemia virus(blv), and use thereof
A kit for detecting bovine leukemia virus (blv) according to the present invention includes: a first pcr primer being oligonucleotide including successive 20 bases or more in the base sequence denoted by seq id no: 1, the first pcr primer being oligonucleotide having 50 bases or less; and second pcr primer being including successive 20 bases or more in the base sequence denoted by seq id no: 2, the second pcr primer being oligonucleotide having 50 bases or less is included.. .
05/29/14
20140147462
Compositions and methods for treatment of hematological malignancies
Use of a chimeric protein selected from the group consisting of ctla4-fasl and cd40-fasl proteins for treatment of lymphoma and/or a multiple myeloma and/or a leukemia as described herein, and pharmaceutical compositions and methods of treatment thereof.. .
05/22/14
20140141513
Cell line of lymphocytes comprising gamma-delta t cells, composition and production method thereof
The present invention shows that human vδ1+ ncr+ t cells can be differentiated and expanded from total γδ peripheral blood lymphocytes (pbls), upon regular in vitro or ex vivo stimulation with γδtcr agonists and γc-family cytokines. This subset surprisingly expresses nkp30, nkp44 and nkp46, and high levels of granzyme b that associate with highly enhanced cytotoxicity against lymphoid leukemias..
05/22/14
20140141410
Feline leukemia virus trans-membrane protein p15e for diagnosis of felv infection
The invention provides for a method for the detection of felv infection in a patient, wherein a sample obtained from the patient is contacted in-vitro with a recombinant transmembrane p15e protein in a p15 (e) antibody binding step.. .
05/15/14
20140135345
Crystalline forms and processes for the preparation of cannabinoid receptor modulators
The present invention relates to crystalline forms of (1as,5as)-2-(4-oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahydro-1h-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid ((s)-1-hydroxymethyl-2,2-dimethyl-propyl)-amide (compound 1) and pharmaceutical compositions thereof that modulate the activity of the cannabinoid cb2 receptor and are therefore useful in the treatment of cb2 receptor-mediated disorders, for example, osteoarthritis; pain; hyperalgesia; allodynia; inflammatory hyperalgesia; neuropathic hyperalgesia; acute nociception; osteoporosis; multiple sclerosis-associated spasticity; autoimmune disorders; allergic reactions; cns inflammation for example; atherosclerosis; undesired immune cell activity, and inflammation associated with a disorder selected from: osteoarthritis, anaphylaxis, behcet's disease, graft rejection, vasculitis, gout, spondylitis, viral disease, bacterial disease, lupus, inflammatory bowel disease, autoimmune hepatitis, and type 1 diabetes mellitus; age-related macular degeneration; cough; leukemia; lymphoma; cns tumors; prostate cancer; alzheimer's disease; stroke-induced damage; dementia; amyotrophic lateral sclerosis; and parkinson's disease.. .
05/08/14
20140128450
Cancer therapy
The present invention provides a method for treating a hyperproliferative disorder characterized by expression of a mutant form of p53 in a subject, the method comprising administering to the subject a therapeutically effective amount of an agent which inhibits promyelocytic leukemia (pml) protein.. .
04/24/14
20140112920
Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
Methods of treating, preventing or managing leukemias are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as revlimid® or lenalidomide.
04/10/14
20140099710
Compositions for the in vitro derivation and culture of embryonic stem (es) cell lines with germline transmission capability and for the culture of adult stem cells
The present invention is directed to a method of deriving pluripotent embryonic stem cells from mouse blastocysts or from primordial germ cells from a post-implantation mouse embryo, or of maintaining or growing pluripotent embryonic stem cells from a mouse, or of expanding human hematopoietic stem cells or human hematopoietic precursor cells. The methods include the step of cultivating the stem cells or precursor cells for at least one passage in a culture medium preconditioned by the rabbit fibroblast cell line rab9 (atcc catalogue crl1414) and containing less than 0.1 ng/ml leukemia inhibitory factor (lif)..
04/03/14
20140094428
Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia
A first aspect of the invention relates to a method of treating aml in a subject, said method comprising administering to a subject a therapeutically effective amount of (i) sapacitabine, or a metabolite thereof; and (ii) decitabine; in accordance with a dosing regimen comprising at least one first treatment cycle and at least one second treatment cycle, wherein said first treatment cycle comprises administering a therapeutically effective amount of decitabine for 5 to 10 consecutive days followed by a rest period of from 3 to 5 weeks, or until treatment-related toxicities are resolved, whichever is longer; and wherein said second treatment cycle comprises administering a therapeutically effective amount of sapacitabine, or a metabolite thereof, for 3 consecutive days per week, for 2 weeks followed by a rest period of from 2 to 4 weeks, or until treatment-related toxicities are resolved, whichever is longer.. .
03/27/14
20140090095
Genetically modified mice and engraftment
A mouse with a humanization of the mil-3 gene and the mgm-csf gene, a knockout of a mrag gene, and a knockout of a mil2rg subunit gene; and optionally a humanization of the tpo gene is described. A rag/il2rg ko/htpo knock-in mouse is described.
03/27/14
20140088088
Anti-cancer activity of novel bicyclic heterocycles
The present invention relates to compound of formula i, ii, iii, or iv, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, formulas (i), (ii), (iii) and (iv) wherein r1, r2, r3, r4, r5, r6, r7, r8, r9, r11, and r12 are as defined in the claim 1 or as described in detail in the description of the invention, and to the use of said compounds to treat or prevent proliferative disorders and their use to manufacture a medicine to treat or prevent proliferative disorders, particularly cancer such as leukemia. The present invention also relates to pharmaceutical compositions of said compounds and the use of said pharmaceutical compositions to treat or prevent proliferative disorders.
03/27/14
20140088052
Chalcone derivatives as nrf2 activators
Compounds and methods for treating or preventing a disease, disorder or condition associated with an nrf2-regulated pathway, including those associated with an autoimmune disease, comorbidity associated with diabetes, such as retinopathy and nephropathy, bone marrow transplant for leukemia and related cancers, bone marrow deficiencies, inborn errors of metabolism, and other immune disorders, oxidative stress, respiratory infection, ischemia, neurodegenerative disorders, radiation injury, neutropenia caused by chemotherapy, autoimmunity, and congenital neutropenic disorders, and for restoring a corticosteroid responsiveness, in a subject are provided.. .


Popular terms: [SEARCH]

Leukemia topics: Myelogenous, Myelogenous Leukemia, Proliferative, Autoimmune, Stem Cells, Breast Cancer, Rheumatoid Arthritis, Myeloid Leukemia, Acute Myelogenous Leukemia, Lymphocytic, Chronic Lymphocytic Leukemia, Lymphocytic Leukemia, Epigenetic, Multiple Myeloma, Polyphenol

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Leukemia for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Leukemia with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.5915

3609

449498 - 0 - 72